Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.

Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.

As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...

William Blair initiated coverage of Vigil Neuroscience (VIGL) with an Outperform rating and $18.67 fair value estimate. Vigil is developing a ...

and Alector-partnered TREM2-directed antibody AL002. Finally, it is testing muscarinic M4 receptor-targeting candidate emraclidine for Alzheimer's-related psychosis in phase 1. "Neuroscience is ...

SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...

A phase I dose escalation study of AL002, in development for the treatment of patients with Alzheimer’s disease, as part of a global strategic partnership with AbbVie, is ongoing. Two additional ...

South Korean Leader’s Fate Is in Doubt as Lawmakers Move to Impeach Him The effort to remove President Yoon Suk Yeol reflected fury over his declaration of martial law. He lifted the order ...

The effort to remove President Yoon Suk Yeol reflected fury over his declaration of martial law. He lifted the order within hours after it incited protests. Members of South Korea’s opposition ...

Dec. 2, 2024 — Scientists now know how many bonobos live in one of the largest pristine tropical forests, a place believed to be the world's stronghold for the ... Dec. 2, 2024 — New research ...

Nov. 27, 2024 — Researchers have quantified for the first time the global emissions of a sulfur gas produced by marine life, revealing it cools the climate more than previously thought ...